Insight Molecular Diagnostics Inc. — Director's Dealing 2018

Mar 30, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2018-03-28

Reporting Person: BROADWOOD PARTNERS, L.P. (10% Owner)
Reporting Person: BROADWOOD CAPITAL INC (10% Owner)
Reporting Person: BRADSHER NEAL C (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-28	Common Stock, no par value	P	3968254	$1.26	Acquired	7564934	Direct
2018-03-28	Common Stock, no par value	P	0	$1.26	Acquired	7564934	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	3145	Direct

Footnotes

F1: On March 28, 2018, the Issuer and Broadwood Partners, L.P. ("BPLP") entered into a Securities Purchase Agreement pursuant to which BPLP purchased 3,968,254 shares of the Issuer's Common Stock, no par value, at a purchase price of $1.26 per share.

F2: These securities are owned by Broadwood Partners, L.P., which is a Reporting Person.

F3: The reported securities are directly owned by Broadwood Partners, L.P. and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners, L.P. and Neal C. Bradsher as President of Broadwood Capital, Inc. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F4: The securities are owned by Neal C. Bradsher, who is a Reporting Person.